Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort studyCraig Haifer, Lena Thin, Ashish Srinivasan et al.|The Medical Journal of Australia|2020Cited by 22
Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort studyCraig Haifer, Lena Thin, Ashish Srinivasan et al.|UWA Profiles and Research Repository (University of Western Australia)|2019Cited by 3
1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIALAviv Pudipeddi, Rupert W. Leong, Caroline Fung et al.|Gastroenterology|2023Cited by 2
Australian Real‐World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the <scp>AURORA</scp> Study, Including the <scp>ANZIBD</scp> ConsortiumYoon‐Kyo An, Jakob Begun, Niamh Lindsay et al.|JGH Open|2025Cited by 1
Tu1749 POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDYYoon‐Kyo An, Jakob Begun, Niamh Lindsay et al.|Gastroenterology|2023Cited by 0